Showing results (121-130 of 154) with videos related to

Sort By:
Pageof 16
Brain : a Journal of Neurology|October 21, 2017
Towards personalized therapy for multiple sclerosis: prediction of individual treatment responseTomas Kalincik, Ali Manouchehrinia, Lukas Sobisek, et al.
JAMA Neurology|June 5, 2023
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab CessationChao Zhu, Tomas Kalincik, Dana Horakova, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 3, 2024
Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort studyCathérine Dekeyser, Matthias Hautekeete, Melissa Cambron, et al.
The Lancet. Neurology|February 18, 2017
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort studyTomas Kalincik, J William L Brown, Neil Robertson, et al.
Neurology|April 21, 2021
Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple SclerosisWei Zhen Yeh, Putu Ayu Widyastuti, Anneke Van der Walt, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 30, 2014
Risk of relapse phenotype recurrence in multiple sclerosisTomas Kalincik, Katherine Buzzard, Vilija Jokubaitis, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 1, 2024
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosisIzanne Roos, Sifat Sharmin, Charles Malpas, et al.
Brain Communications|September 5, 2025
Persistent progression independent of relapse activity in multiple sclerosisChao Zhu, Zhen Zhou, Tomas Kalincik, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase RegistryJuan Ignacio Rojas, Liliana Patrucco, Maria Trojano, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 29, 2022
Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 SeveritySteve Simpson-Yap, Ashkan Pirmani, Tomas Kalincik, et al.
Pageof 16